 ROCKVILLE, Md., March 18, 2021 PRNewswire -- RegeneRx Biopharmaceuticals, Inc. OTCQB: RGRX the Company or RegeneRx, a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome did not meet its primary outcome measures. 